IGHV2-70

Across TCGA pan-cancer cohorts, IGHV2-70 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGHV2-70 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher IGHV2-70 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV2-70 expression acts as an unfavorable survival marker.

LUSC, LIHC, and COAD are the cancer types where IGHV2-70 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.112	0.743	<.001	24	view →
LIHC	DFS	Median	All	0.079	0.553	.003	18	view →
COAD	DFS	Median	All	0.156	0.525	.011	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IGHV2-70–LUSC (OS)

Open the LUSC breakdown →